Eyepoint Pharmaceuticals (NASDAQ:EYPT) Issues Earnings Results, Misses Expectations By $0.03 EPS

Eyepoint Pharmaceuticals (NASDAQ:EYPT) announced its quarterly earnings results on Wednesday. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.03), reports. Eyepoint Pharmaceuticals had a negative net margin of 485.95% and a negative return on equity of 76.13%. The firm had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $1.01 million.

Here are the key takeaways from Eyepoint Pharmaceuticals’ conference call:

• DURAVYU Phase 3 wet AMD program on track — the LUGANO and LUCIA trials are progressing and the company expects top-line data beginning in mid‑2026, using an on‑label aflibercept comparator with planned superiority testing on treatment burden and 6‑month redosing.
• DME pivotal program initiated — first patients have been dosed in the two Phase 3 DME trials (COMO and CAPRI), with randomization underway, rapid enrollment expected via existing site network, and top‑line data targeted in H2 2027.
• Strong cash runway — cash and investments of $306 million (after a $173 million follow‑on in Oct 2025) are expected to fund operations into Q4 2027, supporting Phase 3 programs and NDA preparation.
• Rising costs and wider losses — operating expenses increased materially (Q4 2025: $71M vs $57M; FY 2025: $275M vs $189M) driven by Phase 3 activity, and FY net loss widened to $232M, while revenue declined due to prior deferred revenue recognition.
• Favorable safety and differentiated MOA — in >190 treated patients DURAVYU has shown no ocular/systemic SAEs attributed to the drug, low rates of cataracts (~5.8%), floaters (~5.2%) and ~1% intraocular inflammation, and the company emphasizes a multi‑MOA (VEGF/PDGF/IL‑6 via JAK1) sustained‑release profile aimed at 6‑month dosing.

Eyepoint Pharmaceuticals Stock Performance

Shares of Eyepoint Pharmaceuticals stock traded down $1.30 during trading hours on Thursday, reaching $16.70. 854,372 shares of the company were exchanged, compared to its average volume of 1,404,098. The stock’s fifty day moving average is $15.76 and its 200 day moving average is $14.31. Eyepoint Pharmaceuticals has a 1 year low of $3.91 and a 1 year high of $19.11. The firm has a market cap of $1.38 billion, a PE ratio of -5.59 and a beta of 1.72.

Insider Activity at Eyepoint Pharmaceuticals

In related news, insider Ramiro Ribeiro sold 42,544 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $17.10, for a total value of $727,502.40. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 4.46% of the company’s stock.

Hedge Funds Weigh In On Eyepoint Pharmaceuticals

Several large investors have recently bought and sold shares of the business. Virtus Investment Advisers LLC raised its holdings in Eyepoint Pharmaceuticals by 29.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,638 shares of the company’s stock worth $304,000 after purchasing an additional 3,795 shares in the last quarter. Verition Fund Management LLC acquired a new stake in shares of Eyepoint Pharmaceuticals during the fourth quarter worth about $275,000. Guggenheim Capital LLC acquired a new stake in Eyepoint Pharmaceuticals during the 4th quarter worth approximately $262,000. Rafferty Asset Management LLC purchased a new position in Eyepoint Pharmaceuticals in the 4th quarter valued at $255,000. Finally, Landscape Capital Management L.L.C. purchased a new stake in shares of Eyepoint Pharmaceuticals in the fourth quarter valued at about $229,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Key Stories Impacting Eyepoint Pharmaceuticals

Here are the key news stories impacting Eyepoint Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its price target to $30 and kept a “buy” rating, implying meaningful upside vs. current levels — a catalyst for bullish investor flows. Article Title
• Positive Sentiment: Chardan Capital also raised its target (to $29) and reiterated a “buy,” reinforcing analyst optimism and supporting positive sentiment among growth/biotech investors. Benzinga TickerReport
• Positive Sentiment: Pipeline progress: EyePoint says both pivotal Phase 3 trials for DURAVYU in wet AMD are on track and topline data for DURAVYU (wet AMD and DME) is targeted mid-2026 — a major binary value driver if readouts are positive. Article
• Positive Sentiment: Commercial and balance-sheet setup: company appointed a Chief Commercial Officer to lead launch readiness for DURAVYU and reported >$300M cash & investments as of 12/31/25, giving runway into Q4 2027 — reduces near-term financing risk ahead of pivotal readouts. Press Release
• Neutral Sentiment: Company released Q4 and full-year 2025 results and hosted an earnings call; transcripts are available for detail on guidance, ops and R&D cadence. These provide color but no new surprise beyond the headline miss. Press Release/Transcript Transcript
• Neutral Sentiment: Reported short-interest data in feeds is inconsistent/zeroed out (likely a reporting artifact), so it appears not to be a current driver of volatility. (No link provided.)
• Negative Sentiment: Earnings miss: Q4 EPS of ($0.81) missed consensus (~$0.78) and revenue ($0.62M) fell short of estimates (~$1.01M), reinforcing that EyePoint remains pre-commercial and loss-making until DURAVYU approval/commercialization. Earnings Zacks
• Negative Sentiment: Critical perspective: a Seeking Alpha piece argues the “pre-readout” rally may overlook commercial execution risks and a tougher-than-expected market environment — a narrative that can pressure sentiment among more cautious investors. Seeking Alpha

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on EYPT. HC Wainwright upped their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research report on Thursday. Royal Bank Of Canada increased their price objective on shares of Eyepoint Pharmaceuticals from $28.00 to $39.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Chardan Capital boosted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday. TD Cowen upgraded Eyepoint Pharmaceuticals to a “strong-buy” rating in a research report on Friday, December 19th. Finally, Cantor Fitzgerald raised shares of Eyepoint Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, November 25th. Two research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $31.50.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.